Then you know the study done with doctors and dentists. If that's the case what are you questioning? There was evidence that the "vaccine" wasn't effective and it had negative side effects. What exactly are you trying so pathetically to argue here? Or is this like your windmill studies that you were going to teach us all about? 
PoST tHe StuDiEs.
You made the claim in the windmill thread, I challenged you to back up your claims, you fled in fear.
What is the PMID of the study you think is so damning? There have been a boatload of studies done on both those populations
COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review
Oliver Galgut a,b,c,⁎, Fiona Ashford a, Alexandra Deeks c, Andeep Ghataure d, Mimia Islam d, Tanvir Sambhi d, Yiu Wayn Ker d, Christopher JA Duncan e,f, Thushan I de Silva g,h, Susan Hopkins i,j, Victoria Hall i,k, Paul Klenerman c,l, Susanna Dunachie c,m,n, Alex Richter a,b
Author information
Article notes
Copyright and License information
PMCID: PMC11364133 PMID: 39221179
Abstract
Introduction
Health care workers (HCWs) have been at increased risk of infection during the SARS-CoV-2 pandemic and as essential workers have been prioritised for vaccination. Due to increased exposure HCW are considered a predictor of what might happen in the general population, particularly working age adults. This study aims to summarise effect of vaccination in this ‘at risk’ cohort.
Methods
Ovid MEDLINE and Embase were searched, and 358 individual articles were identified. Of these 49 met the inclusion criteria for review and 14 were included in a meta-analysis.
Results
Participants included were predominantly female and working age. Median time to infection was 51 days. Reported vaccine effectiveness against infection, symptomatic infection, and infection requiring hospitalisation were between 5 and 100 %, 34 and 100 %, and 65 and 100 % (respectively). No vaccinated HCW deaths were recorded in any study. Pooled estimates of protection against infection, symptomatic infection, and hospitalisation were, respectively, 84.7 % (95 % CI 72.6–91.5 %, p < 0.0001), 86.0 % (95 % CI 67.2 %-94.0 %; p < 0.0001), and 96.1 % (95 % CI 90.4 %-98.4 %). Waning protection against infection was reported by four studies, although protection against hospitalisation for severe infection persists for at least 6 months post vaccination.
Conclusions
Vaccination against SARS-CoV2 in HCWs is protective against infection, symptomatic infection, and hospitalisation. Waning protection is reported but this awaits more mature studies to understand durability more clearly. This study is limited by varying non-pharmacological responses to COVID-19 between included studies, a predominantly female and working age population, and limited information on asymptomatic transmission or long COVID protection.
Original Article
Share on
Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel
Authors: Tamara Pilishvili, Ph.D., M.P.H., Ryan Gierke, M.P.H., Katherine E. Fleming-Dutra, M.D., Jennifer L. Farrar, M.P.H., Nicholas M. Mohr, M.D., David A. Talan, M.D., Anusha Krishnadasan, Ph.D., +38 , for the Vaccine Effectiveness among Healthcare Personnel Study Team*Author Info & Affiliations
Published September 22, 2021
N Engl J Med 2021;385: e90
DOI: 10.1056/NEJMoa2106599
VOL. 385 NO. 25
Copyright © 2021
Information & Authors
Metrics & Citations
References
Media
Tables
Share
Abstract
Background
The prioritization of U.S. health care personnel for early receipt of messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), allowed for the evaluation of the effectiveness of these new vaccines in a real-world setting.
Methods
We conducted a test-negative case–control study involving health care personnel across 25 U.S. states. Cases were defined on the basis of a positive polymerase-chain-reaction (PCR) or antigen-based test for SARS-CoV-2 and at least one Covid-19–like symptom. Controls were defined on the basis of a negative PCR test for SARS-CoV-2, regardless of symptoms, and were matched to cases according to the week of the test date and site. Using conditional logistic regression with adjustment for age, race and ethnic group, underlying conditions, and exposures to persons with Covid-19, we estimated vaccine effectiveness for partial vaccination (assessed 14 days after receipt of the first dose through 6 days after receipt of the second dose) and complete vaccination (assessed ≥7 days after receipt of the second dose).
Research Summary
Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel
Results
The study included 1482 case participants and 3449 control participants. Vaccine effectiveness for partial vaccination was 77.6% (95% confidence interval [CI], 70.9 to 82.7) with the BNT162b2 vaccine (Pfizer–BioNTech) and 88.9% (95% CI, 78.7 to 94.2) with the mRNA-1273 vaccine (Moderna); for complete vaccination, vaccine effectiveness was 88.8% (95% CI, 84.6 to 91.

and 96.3% (95% CI, 91.3 to 98.4), respectively. Vaccine effectiveness was similar in subgroups defined according to age (<50 years or ≥50 years), race and ethnic group, presence of underlying conditions, and level of patient contact. Estimates of vaccine effectiveness were lower during weeks 9 through 14 than during weeks 3 through 8 after receipt of the second dose, but confidence intervals overlapped widely.
Conclusions
The BNT162b2 and mRNA-1273 vaccines were highly effective under real-world conditions in preventing symptomatic Covid-19 in health care personnel, including those at risk for severe Covid-19 and those in racial and ethnic groups that have been disproportionately affected by the pandemic. (Funded by the Centers for Disease Control and Prevention.)
Prove your point lil guy. The vaccines were effective and safe.
A meta analysis- second only to the cochrane review in medicine
Meta-Analysis Rev Med Virol
. 2024 Jan;34(1):e2507. doi: 10.1002/rmv.2507.
Safety and efficacy of COVID-19 vaccines: A systematic review and meta-analysis of controlled and randomized clinical trials
Jayesh Beladiya 1, Anup Kumar 1, Yogesh Vasava 1, Krupanshu Parmar 1, Dipanshi Patel 1, Sandip Patel 1, Sandip Dholakia 2, Devang Sheth 1, Sai H S Boddu 3 4, Chirag Patel 1
Affiliations Expand
PMID: 38282394 DOI: 10.1002/rmv.2507
Abstract
Vaccines against coronavirus disease 2019 (COVID-19) have been discovered within a very small duration of time as compared to the traditional way for the development of vaccines, which raised the question about the safety and efficacy of the approved vaccines. The purpose of this study is to look at the effectiveness and safety of vaccine platforms against the incidence of COVID-19. The literature search was performed on PubMed/Medline, Cochrane, and clinical trials.gov databases for studies published between 1 January 2020 and 19 February 2022. Preferred Reporting Items for Systemic Review and Meta-Analysis Statement guidelines were followed. Among 284 articles received by keywords, a total of 11 studies were eligible according to the inclusion and exclusion criteria (studies in special populations, e.g., pregnant women, paediatric patients, editorials, case reports, review articles, preclinical and in vitro studies) of the study. A total of 247,186 participants were considered for randomisation at baseline, among them, 129,572 (52.42%) were provided with vaccine (Intervention group) and 117,614 (47.58%) with the placebo (Control group). A pooled fold change estimation of 0.19 (95% CI: 0.12-0.31, p < 0.0001) showed significant protection against the incidence of COVID-19 in the vaccines received group versus the placebo group. mRNA based, inactivated vaccines and non-replicating viral vector-based vaccines showed significantly protection against the incidence of COVID-19 compared to placebo with pooled fold change estimation was 0.08 (95% CI: 0.06-0.10), 0.20 (95% CI: 0.14-0.29) and 0.36 (95% CI: 0.28-0.46), respectively. Injection site discomfort and fatigue were the most common side effect observed in mRNA, non-replicating viral vector, inactivated, and protein subunit-based vaccines. All the approved vaccines were found safe and efficacious but mRNA-based vaccines were found to be more efficacious against SARS-CoV-2 than other platforms.
If you are not familiar with stats I can break that down further for you. Send over the study. I would like to have a look